Meta-Analysis
Copyright ©The Author(s) 2022.
World J Clin Cases. Nov 26, 2022; 10(33): 12230-12239
Published online Nov 26, 2022. doi: 10.12998/wjcc.v10.i33.12230
Table 1 Basic characteristics of included studies
Ref.CountrySample sizeTumor typeTNM stageTreatmentCutoff value of ferritin (ng/dL)NOS
Endpoint
Selection
Comparability
Outcome
Overall
Milman et al[17], 1991Denmark31SCLCLimited and advancedNon-surgery4003036OS
Ferrigno et al[18], 1992Italy168LCI-IVMixed2364026OS
Milman et al[19], 2002Denmark90NSCLCI-IVMixed3004037OS
Milman et al[19], 2002Denmark25SCLCLimited and advancedMixed3003036OS
Erbaycu et al[20], 2008Turkey41LCI-IVMixed2203036OS
Zhao et al[21], 2014China69LCIVNon-surgeryNR4037OS
Xie et al[22], 2018China72SCLCLimited and advancedNRNR4037OS
Lee et al[23], 2019Republic of Korea138NSCLCIIIB-IVNon-surgery2004037OS
Ma et al[24], 2019China393NSCLCI-IIINR382.654037OS
Sun[25], 2020China72NSCLCIII-IVNon-surgeryMale: 200, female: 1503036OS
Ji et al[26], 2021China69NSCLCIIIB-IVNon-surgery311.13036OS
Xiao[27], 2021China86SCLCNRNRNR3036OS
Zhu[28], 2021China400LCI-IVNR114.14037OS
Table 2 Results of meta-analysis

No. of studies
HR
95%CI
P value
I2 (%)
Pheterogeneity
Overall survival12 (17-28)1.091.03-1.150.00486.5< 0.001
Country
Non-China5 (17-20, 23)1.611.27-2.03< 0.0010.00.760
China7 (21, 22, 24-28)1.061.00-1.120.04291.5< 0.001
Tumor type
SCLC4 (17, 19, 22, 27)1.990.74-5.350.17590.7< 0.001
LC4 (18, 20, 21, 28)1.391.09-1.770.0080.00.666
NSCLC5 (19, 23-26)1.030.98-1.070.28186.2< 0.001